Hundreds of people living with motor neurone disease are being invited to take part in one of the UK's most comprehensive clinical trials in a generation.
The UK-wide trial - called MND-SMART - aims to find treatments that can slow, stop or reverse disease progression.
The long-term study will ensure that new medicines can be tested for years to come, researchers say.
Motor neurone disease (MND), also known as amyotrophic lateral sclerosis or ALS, is a progressive condition that causes muscle to waste away.
It occurs when nerve cells called motor neurons, which send messages from the brain and spinal cord to the body's muscles, stop working properly.
More than 1500 people are diagnosed with MND in the UK each year. There is no cure and half of people die within two years of diagnosis.
MND-SMART will include as many people with the condition as possible, regardless of how the disease or current treatments affect them. The trial has been developed to find effective medicines more quickly.
Typical clinical trials focus on a single drug - patients receiving the active drug are compared with those who receive an inactive substance, known as the placebo. MND-SMART will allow more than one treatment to be tested against a shared placebo group so that patients have a higher likelihood of receiving an active treatment.
The clinical trial is designed to be adaptive so that the researchers can modify their approach according to emerging results. New drugs can be added once the trial has started, while medicines that prove ineffective can be dropped.
Initially researchers will test drugs that are already licensed for use in other conditions to check whether they offer any benefit for people with MND.
This repurposing of existing drugs avoids some of the lengthy approvals processes associated with new drugs and could cut years off the time taken for the medications to become available to people with MND through the NHS.
People with MND are invited to register interest in the trial at http://www.MND-SMART.org The first participants will be seen in Edinburgh with other clinics across the UK joining during 2020. Related Stories
Also in Industry News
How to decide whether or not to start treatment for prostate cancer?
Analysis of the SARS-CoV-2 proteome via visual tools
$65m investment increases British Patient Capital’s exposure to life sciences and health technology